5-day course of ivermectin may reduce duration of COVID-19

Organisation: Position: Deadline Date: Location:

Ivermectin, an FDA-approved anti-parasitic agent, was found to be an inhibitor of SARS-CoV-2 replication in the laboratory and a Bangladesh study found that it may be effective for the treatment of early-onset mild Covid-19 in adult patients.

According to the study, published in the International Journal of Infectious Diseases, early viral clearance of SARS-CoV-2 was observed in treated patients. Remission of fever, cough and sore throat did not differ between those treated with or without ivermectin. No severe adverse event observed with the longer duration of ivermectin use.

Larger trials will be needed to confirm these preliminary findings, the authors noted.

Study details

A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G. Ross, Mohammad Sharif Hossain, John D. Clemens, Mariya, Kibtiya Sumiya, Ching Swe Phru, Mustafizur Rahman, Khalequ Zaman, Jyoti Somani, Rubina Yasmin, Mohammad Abul Hasnat, Ahmedul Kabir, Asma Binte Aziz, Wasif Ali Khan

International Journal of Infectious Diseases, 2 December 2020

Highlights
• Ivermectin, an FDA-approved anti-parasitic agent, was found to be an inhibitor of SARS-CoV-2 replication in the laboratory.
• Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.
• Early viral clearance of SARS-CoV-2 was observed in ivermectin treated patients.
• Remission of fever, cough and sore throat did not differ among treatment groups. No severe adverse event was observed.
• Larger trials will be needed to confirm these preliminary findings.

Abstract

Ivermectin, an FDA-approved anti-parasitic agent, was found in vitro to inhibit SARS-CoV-2 replication. To determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients we conducted a randomized, double-blind, placebo-controlled trial of oral ivermectin alone (12 mg once daily for 5 days) or in combination with doxycycline (12 mg ivermectin single dose and 200 mg stat doxycycline day-1 followed by 100 mg 12hrly for next 4 days) compared with placebo among 72 hospitalized patients in Dhaka, Bangladesh. Clinical symptoms of fever, cough and sore throat were comparable among the three treatment arms. Virological clearance was earlier in the 5-day ivermectin treatment arm versus the placebo group (9.7 days vs. 12.7 days; P = 0.02); but not with the ivermectin + doxycycline arm (11.5 days; P = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating mild COVID-19 adult patients. Larger trials will be needed to confirm these preliminary findings.

 

Full text in the International Journal of Infectious Diseases (Open access)

 

MedicalBrief Archives: Ivermectin stops SARS-COV2 growing in cell culture within 48 hours(Open access)

 

See in MedicalBrief Archives

Lower mortality for hospitalised COVID-19 patients taking Ivermectin – ICON study

 


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.